A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.
At the European Patent Office (EPO), GlaxoSmithKline (GSK) challenged a patent owned by US research group the Institute for Systems Biology (ISB), on numerous grounds of opposition including lack of novelty and inventive step.
ISB’s application for a European patent (EP) is directed to the medical use of a peptide that induces an immune response and is based on an international patent application claiming priority of a US patent application filed in 2001.
Until recently, the US Patent and Trademark Office required that all patent applications name the inventor as the applicant, whereas international applications claiming US priority will often name a company, usually the inventor’s employer, as the applicant.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
EPO, GlaxoSmithKline, Institute for Systems Biology, EP, entitlement to priority